Announced
Completed
Financials
Tags
biotherapeutic
medical devices
biological products
Majority
molecular diagnostics
Completed
Private
Acquisition
Natural
United States
Biotechnology
Single Bidder
Synopsis
Evotec will pay a total consideration of up to $ 90m including potential earn outs in the next three years. The initial consideration upon closing is $ 60m subject to customary net debt and working capital adjustments. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash to a syndicate of institutional investors of ARCH Venture Partners, Merck & Co, Lilly Asia Ventures and the Bill & Melinda Gates Foundation. “With the integration of Just.Bio’s expertise in biologics and their outstanding human talent, we will accelerate our ability to build better molecules with cutting-edge technologies for our customers as well as our own pipeline. We warmly welcome the Just.Bio employees to the Evotec Group.” Dr Werner Lanthaler, Chief Executive Officer of Evotec. “Starting with a small group of creative and passionate employees, we've made remarkably fast progress building a state-of-the-art technology platform for expanding global access to biologics. Joining forces with Evotec will build upon these accomplishments and accelerate expansion of our advanced capabilities in Seattle, a growing hub of technology innovation. We are thrilled to be part of the excellent Evotec global team.” Dr James Thomas, EVP, Global Head, Biotherapeutics, President US Operations of Evotec.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.